Pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer, is one of the most aggressive and lethal malignancies. The lack of adequate treatment might in part be related to the fact that none of the proposed strategies targets PDAC-induced cachexia, an anorexic state characterized by systemic and hypothalamic inflammation, and a major cause of PDAC morbidity and mortality. PDAC patients also suffer from mood disturbances, which in turn
can affect tumor progression. With this project we intend to investigate the potential of system xc- inhibition to treat PDAC as well as PDAC-related cachexia and mood disturbances. System xc- is a cystine/glutamate antiporter, which is enhanced on cancer cells to provide increased antioxidant capacity allowing them to grow and resist to chemo- and radiotherapy. Besides reducing tumor growth and progression, inhibition of system xc- has the potential to reduce PDAC-induced (neuro)inflammation, attenuate cachexia and induce anti-depressive as well as anxiolytic effects. One treatment strategy might as such act not only directly on the tumor but also on different cancer-related comorbidities. We will here study the effect of genetic deletion of system xc- on tumor cells and/or the entire organism in a mouse PDAC model. This strategy will not only give insight into the potential of system xc- inhibition as treatment strategy, but also into the mechanisms, thereby allowing optimization of the treatment.
Effective start/end date1/10/1830/09/22

    Flemish discipline codes

  • Cancer biology

    Research areas

  • PDAC, Cancer

ID: 38836375